Skip to main content
Publish date:

Alkermes To Take Part In Stifel's 3rd Annual CNS Day

DUBLIN, March 25, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at Stifel's 3 rd Annual CNS Day on Thursday, Apr.

DUBLIN, March 25, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at Stifel's 3 rd Annual CNS Day on Thursday, Apr. 1, 2021 at 8:30 a.m. ET ( 1:30 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes'  website at   www.alkermes.com .

Contact: Alex BraunInvestor Relations+1 781 296 8493

View original content to download multimedia: http://www.prnewswire.com/news-releases/alkermes-to-take-part-in-stifels-3rd-annual-cns-day-301256281.html

SOURCE Alkermes plc